Certara (NASDAQ:CERT) Sets New 1-Year High - Here's Why

Key Points

• Certara shares reached a new 52-week high of $12.00, then traded at $11.17, up from the prior close of $11.09.
• Analyst views are mixed: the consensus rating is Hold, with an average price target of $9.18, though KeyCorp raised its target to $12 and rated the stock overweight.
• Quarterly EPS of $0.09 matched expectations, while revenue of $94.9 million topped forecasts but fell 9.3% year over year.

Certara, Inc. (NASDAQ:CERT - Get Free Report) shares hit a new 52-week high on Thursday. The stock traded as high as $12.00 and last traded at $11.17, with a volume of 197,349 shares trading hands. The stock had previously closed at $11.09.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. TD Cowen boosted their target price on shares of Certara from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, October 13th. UBS Group downgraded Certara from a "buy" rating to a "neutral" rating and set a $10.00 price target on the stock. in a research report on Wednesday, September 30th. Weiss Ratings lowered shares of Certara from a "sell (d)" rating to a "sell (d-)" rating in a research report on Thursday, October 8th. Barclays upped their target price on Certara from $7.50 to $9.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. Finally, KeyCorp upped their price target on Certara from $9.00 to $12.00 and gave the company an "overweight" rating in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $9.18.

Certara Price Performance

The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a 50 day simple moving average of $9.18 and a 200 day simple moving average of $7.32. The stock has a market cap of $1.73 billion, a P/E ratio of -25.24 and a beta of 1.30.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, hitting the consensus estimate of $0.09. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company had revenue of $94.90 million during the quarter, compared to analysts' expectations of $92.01 million. During the same period last year, the business earned $0.14 EPS. The business's quarterly revenue was down 9.3% on a year-over-year basis. Sell-side analysts forecast that Certara, Inc. will post 0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Certara

Large investors have recently modified their holdings of the business. Deutsche Bank AG acquired a new position in Certara during the second quarter valued at approximately $803,000. Haveli Investment Management LLC acquired a new position in shares of Certara during the 2nd quarter worth approximately $48,470,000. Granite Investment Partners LLC bought a new stake in shares of Certara during the 1st quarter worth approximately $2,130,000. Bank of New York Mellon Corp bought a new stake in shares of Certara during the 2nd quarter worth approximately $4,788,000. Finally, BlackRock Inc. acquired a new stake in shares of Certara in the 2nd quarter valued at approximately $123,259,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.